MARKET RELEASE

28 June 2016

Mayne Pharma Group Limited

TRADING HALT

The securities of Mayne Pharma Group Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the commencement of normal trading on Thursday, 30 June 2016.

Security Code: MYX

Cheng Tang

ADVISER, LISTINGS (MELBOURNE)

ASX Compliance
Pty Limited
ABN 26 087 780 489

20 Bridge Street
Sydney NSW 2000

www.asx.com.au
Customer service 13 12 79

(03) 9617 8772
cheng.tang@asx.com.au

28 June 2016

The Manager
Company Notices Section
ASX Limited
Rialto Towers
Level 45, 525 Collins Street
MELBOURNE VIC 3000

Dear Sir/Madam

Mayne Pharma Group Limited – Request for Trading Halt

The directors of Mayne Pharma Group Limited ACN 115 832 963 (ASX: MYX) (**Mayne Pharma**) request a trading halt from the commencement of trading on 28 June 2016 at which time Mayne Pharma proposes to announce an accelerated non-renounceable entitlement offer and institutional placement (together, **Capital Raising**) to fund an acquisition.

The trading halt is requested to facilitate the conduct of a bookbuild for the Capital Raising.

For the purposes of ASX Listing Rule 17.1, Mayne Pharma provides the following further information:

(a) Mayne Pharma expects that the trading halt will remain in place until the commencement of trading on 30 June 2016, unless, before that time, Mayne Pharma requests that the trading halt be lifted; and

(b) Mayne Pharma is not aware of any reason why the trading halt should not be granted.

If you have any queries, please do not hesitate to contact the writer.

Yours faithfully,
Mayne Pharma Group Limited

Mark Candsale
Group CFO and Company Secretary

mayne pharma
Mayne Pharma Group Limited
ABN 76 115 832 963
maynepharma.com
T +61 3 8614 7777 F +61 3 9614 7022
Level 1, 99 King Street, Melbourne, VIC 3000 Australia